Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998-2020).
Anti-malarial drug
Cameroon
Efficacy
Malaria
Mutations
Plasmodium falciparum
Resistance
Systematic review
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
09 Jan 2021
09 Jan 2021
Historique:
received:
17
09
2020
accepted:
10
12
2020
entrez:
10
1
2021
pubmed:
11
1
2021
medline:
20
7
2021
Statut:
epublish
Résumé
Malaria remains highly endemic in Cameroon. The rapid emergence and spread of drug resistance was responsible for the change from monotherapies to artemisinin-based combinations. This systematic review and meta-analysis aimed to determine the prevalence and distribution of Plasmodium falciparum drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon from January 1998 to August 2020. The PRISMA-P and PRISMA statements were adopted in the inclusion of studies on single nucleotide polymorphisms (SNPs) of P. falciparum anti-malarial drug resistance genes (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, Pfatp6, Pfcytb and Pfk13). The heterogeneity of the included studies was evaluated using the Cochran's Q and I Out of the 902 records screened, 48 studies were included in this aggregated meta-analysis of molecular data. A total of 18,706 SNPs of the anti-malarial drug resistance genes were genotyped from 47,382 samples which yielded a pooled prevalence of 35.4% (95% CI 29.1-42.3%). Between 1998 and 2020, there was significant decline (P < 0.0001 for all) in key mutants including Pfcrt 76 T (79.9%-43.0%), Pfmdr1 86Y (82.7%-30.5%), Pfdhfr 51I (72.2%-66.9%), Pfdhfr 59R (76.5%-67.8%), Pfdhfr 108 N (80.8%-67.6%). The only exception was Pfdhps 437G which increased over time (30.4%-46.9%, P < 0.0001) and Pfdhps 540E that remained largely unchanged (0.0%-0.4%, P = 0.201). Exploring mutant haplotypes, the study observed a significant increase in the prevalence of Pfcrt CVIET mixed quintuple haplotype from 57.1% in 1998 to 57.9% in 2020 (P < 0.0001). In addition, within the same study period, there was no significant change in the triple Pfdhfr IRN mutant haplotype (66.2% to 67.3%, P = 0.427). The Pfk13 amino acid polymorphisms associated with artemisinin resistance were not detected. This review reported an overall decline in the prevalence of P. falciparum gene mutations conferring resistance to 4-aminoquinolines and amino alcohols for a period over two decades. Resistance to artemisinins measured by the presence of SNPs in the Pfk13 gene does not seem to be a problem in Cameroon. Systematic review registration PROSPERO CRD42020162620.
Sections du résumé
BACKGROUND
BACKGROUND
Malaria remains highly endemic in Cameroon. The rapid emergence and spread of drug resistance was responsible for the change from monotherapies to artemisinin-based combinations. This systematic review and meta-analysis aimed to determine the prevalence and distribution of Plasmodium falciparum drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon from January 1998 to August 2020.
METHODS
METHODS
The PRISMA-P and PRISMA statements were adopted in the inclusion of studies on single nucleotide polymorphisms (SNPs) of P. falciparum anti-malarial drug resistance genes (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, Pfatp6, Pfcytb and Pfk13). The heterogeneity of the included studies was evaluated using the Cochran's Q and I
RESULTS
RESULTS
Out of the 902 records screened, 48 studies were included in this aggregated meta-analysis of molecular data. A total of 18,706 SNPs of the anti-malarial drug resistance genes were genotyped from 47,382 samples which yielded a pooled prevalence of 35.4% (95% CI 29.1-42.3%). Between 1998 and 2020, there was significant decline (P < 0.0001 for all) in key mutants including Pfcrt 76 T (79.9%-43.0%), Pfmdr1 86Y (82.7%-30.5%), Pfdhfr 51I (72.2%-66.9%), Pfdhfr 59R (76.5%-67.8%), Pfdhfr 108 N (80.8%-67.6%). The only exception was Pfdhps 437G which increased over time (30.4%-46.9%, P < 0.0001) and Pfdhps 540E that remained largely unchanged (0.0%-0.4%, P = 0.201). Exploring mutant haplotypes, the study observed a significant increase in the prevalence of Pfcrt CVIET mixed quintuple haplotype from 57.1% in 1998 to 57.9% in 2020 (P < 0.0001). In addition, within the same study period, there was no significant change in the triple Pfdhfr IRN mutant haplotype (66.2% to 67.3%, P = 0.427). The Pfk13 amino acid polymorphisms associated with artemisinin resistance were not detected.
CONCLUSIONS
CONCLUSIONS
This review reported an overall decline in the prevalence of P. falciparum gene mutations conferring resistance to 4-aminoquinolines and amino alcohols for a period over two decades. Resistance to artemisinins measured by the presence of SNPs in the Pfk13 gene does not seem to be a problem in Cameroon. Systematic review registration PROSPERO CRD42020162620.
Identifiants
pubmed: 33422080
doi: 10.1186/s12936-020-03543-8
pii: 10.1186/s12936-020-03543-8
pmc: PMC7796563
doi:
Substances chimiques
Antimalarials
0
Genetic Markers
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : DELTAS Africa/Wellcome trust
ID : DEL-15-010
Références
Am J Trop Med Hyg. 1999 Nov;61(5):807-13
pubmed: 10586916
PLoS Med. 2008 Nov 25;5(11):e226; discussion e226
pubmed: 19067479
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Am J Trop Med Hyg. 2003 Nov;69(5):558-63
pubmed: 14695097
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
Malar J. 2018 Nov 7;17(1):413
pubmed: 30404640
Am J Trop Med Hyg. 2002 Oct;67(4):392-5
pubmed: 12455497
Malar J. 2011 Jul 20;10:198
pubmed: 21774826
Front Public Health. 2019 Apr 24;7:95
pubmed: 31069209
Malar J. 2009 Jun 08;8:125
pubmed: 19505304
Malar J. 2014 Apr 21;13:152
pubmed: 24751352
Am J Trop Med Hyg. 2017 Jul;97(1):222-224
pubmed: 28719312
Am J Trop Med Hyg. 2002 Jun;66(6):667-71
pubmed: 12224572
J Infect Dis. 2006 Jun 15;193(12):1738-41
pubmed: 16703518
Nat Med. 2020 Oct;26(10):1602-1608
pubmed: 32747827
CMAJ. 1988 Feb 1;138(3):240-1
pubmed: 3276377
Proc Natl Acad Sci U S A. 1990 Apr;87(8):3014-7
pubmed: 2183221
Malar J. 2017 Jan 13;16(1):28
pubmed: 28086777
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Malar J. 2009 Jul 29;8:176
pubmed: 19640292
Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):220-229
pubmed: 27821281
J Microbiol Methods. 2003 Sep;54(3):391-401
pubmed: 12842486
Proc Natl Acad Sci U S A. 1988 Dec;85(23):9114-8
pubmed: 2904149
J Infect Dis. 2015 Apr 15;211(8):1352-5
pubmed: 25367300
PLoS Med. 2009 Apr 14;6(4):e1000055
pubmed: 19365539
J Infect Dis. 2001 Jun 15;183(12):1828-31
pubmed: 11372041
Am J Trop Med Hyg. 1998 Oct;59(4):577-81
pubmed: 9790433
Am J Trop Med Hyg. 2002 Oct;67(4):383-7
pubmed: 12455495
Cent Afr J Med. 2001 Jun;47(6):145-9
pubmed: 12201020
Antimicrob Agents Chemother. 2008 Nov;52(11):4089-97
pubmed: 18765692
Malar J. 2012 Dec 27;11:433
pubmed: 23270636
Sci Rep. 2020 Feb 26;10(1):3500
pubmed: 32103124
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3515-3520
pubmed: 28289193
PLoS One. 2019 Sep 3;14(9):e0221895
pubmed: 31479501
Malar J. 2009 May 04;8:89
pubmed: 19413906
Infect Dis Poverty. 2017 Nov 6;6(1):136
pubmed: 29110722
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Malar J. 2019 Mar 26;18(1):101
pubmed: 30914041
Am J Trop Med Hyg. 1998 Mar;58(3):369-73
pubmed: 9546421
Am J Trop Med Hyg. 2018 Apr;98(4):1132-1136
pubmed: 29436339
Am J Trop Med Hyg. 2003 Aug;69(2):179-83
pubmed: 14506774
N Engl J Med. 2001 Jan 25;344(4):257-63
pubmed: 11172152
Malar J. 2010 Jan 27;9:34
pubmed: 20105282
Antimicrob Agents Chemother. 2019 Oct 7;:
pubmed: 31591113
Lancet. 2004 Jul 31-Aug 6;364(9432):438-447
pubmed: 15288742
Am J Trop Med Hyg. 1999 Nov;61(5):802-6
pubmed: 10586915
Am J Trop Med Hyg. 2000 Feb;62(2):271-6
pubmed: 10813484
Malar J. 2012 Apr 12;11:113
pubmed: 22498364
Am J Trop Med Hyg. 2003 Aug;69(2):174-8
pubmed: 14506773
J Infect Dis. 2000 Aug;182(2):624-8
pubmed: 10915101
BMJ Glob Health. 2018 Oct 19;3(5):e000999
pubmed: 30397515
Am J Trop Med Hyg. 2011 Jul;85(1):22-5
pubmed: 21734119
Proc Natl Acad Sci U S A. 1988 Dec;85(23):9109-13
pubmed: 3057499
Antimicrob Agents Chemother. 1998 Jul;42(7):1811-4
pubmed: 9661026
Malar J. 2011 Aug 25;10:250
pubmed: 21867552
PLoS One. 2013 Oct 30;8(10):e77775
pubmed: 24204960
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Malar Res Treat. 2018 May 2;2018:7071383
pubmed: 29854394
Malar J. 2015 Jan 28;14:27
pubmed: 25626448
J Antimicrob Chemother. 2014 Feb;69(2):400-3
pubmed: 24092656
Int J Parasitol Drugs Drug Resist. 2020 Apr;12:1-6
pubmed: 31809965
Am J Trop Med Hyg. 2002 Oct;67(4):388-91
pubmed: 12455496
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13944-9
pubmed: 9391132
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29941645
Malar J. 2013 Oct 30;12:377
pubmed: 24172030
Acta Trop. 2007 Aug;103(2):81-9
pubmed: 17640607
Am J Trop Med Hyg. 2007 Aug;77(2):221-7
pubmed: 17690390
JAMA. 2013 Feb 13;309(6):594-604
pubmed: 23403684
Infect Genet Evol. 2006 Jul;6(4):262-8
pubmed: 16154388
Malar J. 2019 Mar 7;18(1):60
pubmed: 30846002
Am J Trop Med Hyg. 2014 Oct;91(4):833-843
pubmed: 25048375
Parasit Vectors. 2017 Jul 26;10(1):355
pubmed: 28747223
Malar J. 2010 Feb 19;9:56
pubmed: 20170477
Braz Dent J. 2019 Nov-Dec;30(6):527-535
pubmed: 31800745
Malar J. 2008 Jan 19;7:16
pubmed: 18205945
Antimicrob Agents Chemother. 2010 Jul;54(7):3049-51
pubmed: 20404118
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30803964
Mem Inst Oswaldo Cruz. 2012 Feb;107(1):129-34
pubmed: 22310546
Malar J. 2017 Mar 27;16(1):130
pubmed: 28347314
Lancet. 1985 May 18;1(8438):1154-5
pubmed: 2860354
Ann Trop Med Parasitol. 2007 Mar;101(2):95-102
pubmed: 17316495
PLoS One. 2016 Mar 31;11(3):e0151565
pubmed: 27031231
Trans R Soc Trop Med Hyg. 1989 May-Jun;83(3):308-10
pubmed: 2694461
Am J Trop Med Hyg. 2002 Oct;67(4):378-82
pubmed: 12452492
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14216-21
pubmed: 18780786
Malar J. 2016 Nov 26;15(1):572
pubmed: 27887614
Malar J. 2014 Dec 04;13:472
pubmed: 25471113
Malar J. 2009 Apr 14;8:63
pubmed: 19366448
Biomedicines. 2016 Feb 15;4(1):
pubmed: 28536372
PLoS One. 2013 Jul 26;8(7):e69930
pubmed: 23922860
Am J Trop Med Hyg. 2009 Jul;81(1):13-8
pubmed: 19556559
J Antimicrob Chemother. 2015 Sep;70(9):2566-71
pubmed: 26080363
Am J Trop Med Hyg. 2006 Sep;75(3):396-401
pubmed: 16968912
J Infect Dis. 2006 Aug 15;194(4):528-35
pubmed: 16845638
Malar J. 2009 Jan 12;8:11
pubmed: 19138391
PLoS One. 2013 Jul 24;8(7):e69505
pubmed: 23894496
Malar J. 2010 Jun 18;9:174
pubmed: 20565881
J Infect Dis. 2014 Dec 15;210(12):1962-71
pubmed: 24943722